IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety...
Uloženo v:
| Vydáno v: | British journal of cancer Ročník 122; číslo 11; s. 1580 - 1589 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
26.05.2020
Nature Publishing Group |
| Témata: | |
| ISSN: | 0007-0920, 1532-1827, 1532-1827 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety of human malignancies, including gliomas, acute myeloid leukaemia, cholangiocarcinoma, chondrosarcoma and thyroid carcinoma. A series of seminal studies further elucidated the biological impact of the IDH mutation and uncovered the potential role of IDH mutants in oncogenesis. Notably, the neomorphic activity of the IDH mutants establishes distinctive patterns in cancer metabolism, epigenetic shift and therapy resistance. Novel molecular targeting approaches have been developed to improve the efficacy of therapeutics against IDH-mutated cancers. Here we provide an overview of the latest findings in IDH-mutated human malignancies, with a focus on glioma, discussing unique biological signatures and proceedings in translational research. |
|---|---|
| AbstractList | Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety of human malignancies, including gliomas, acute myeloid leukaemia, cholangiocarcinoma, chondrosarcoma and thyroid carcinoma. A series of seminal studies further elucidated the biological impact of the IDH mutation and uncovered the potential role of IDH mutants in oncogenesis. Notably, the neomorphic activity of the IDH mutants establishes distinctive patterns in cancer metabolism, epigenetic shift and therapy resistance. Novel molecular targeting approaches have been developed to improve the efficacy of therapeutics against IDH-mutated cancers. Here we provide an overview of the latest findings in IDH-mutated human malignancies, with a focus on glioma, discussing unique biological signatures and proceedings in translational research. Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety of human malignancies, including gliomas, acute myeloid leukaemia, cholangiocarcinoma, chondrosarcoma and thyroid carcinoma. A series of seminal studies further elucidated the biological impact of the IDH mutation and uncovered the potential role of IDH mutants in oncogenesis. Notably, the neomorphic activity of the IDH mutants establishes distinctive patterns in cancer metabolism, epigenetic shift and therapy resistance. Novel molecular targeting approaches have been developed to improve the efficacy of therapeutics against IDH-mutated cancers. Here we provide an overview of the latest findings in IDH-mutated human malignancies, with a focus on glioma, discussing unique biological signatures and proceedings in translational research.Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety of human malignancies, including gliomas, acute myeloid leukaemia, cholangiocarcinoma, chondrosarcoma and thyroid carcinoma. A series of seminal studies further elucidated the biological impact of the IDH mutation and uncovered the potential role of IDH mutants in oncogenesis. Notably, the neomorphic activity of the IDH mutants establishes distinctive patterns in cancer metabolism, epigenetic shift and therapy resistance. Novel molecular targeting approaches have been developed to improve the efficacy of therapeutics against IDH-mutated cancers. Here we provide an overview of the latest findings in IDH-mutated human malignancies, with a focus on glioma, discussing unique biological signatures and proceedings in translational research. |
| Author | Qian, Mingyu Cai, Sabrina J. Yang, Chunzhang Ding, Jianyi Han, Sue Liu, Yang Gilbert, Mark R. Larion, Mioara |
| Author_xml | – sequence: 1 givenname: Sue surname: Han fullname: Han, Sue organization: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute – sequence: 2 givenname: Yang surname: Liu fullname: Liu, Yang organization: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute – sequence: 3 givenname: Sabrina J. surname: Cai fullname: Cai, Sabrina J. organization: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute – sequence: 4 givenname: Mingyu surname: Qian fullname: Qian, Mingyu organization: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute – sequence: 5 givenname: Jianyi surname: Ding fullname: Ding, Jianyi organization: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute – sequence: 6 givenname: Mioara surname: Larion fullname: Larion, Mioara organization: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute – sequence: 7 givenname: Mark R. surname: Gilbert fullname: Gilbert, Mark R. organization: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute – sequence: 8 givenname: Chunzhang surname: Yang fullname: Yang, Chunzhang email: yangc2@nih.gov organization: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32291392$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU9v1DAQxS1URLeFD8AFReLCJTD-t445IFVtoZUquMDZcpzZXVeJvdgOKt8el5QCleBkjfx7M2_mHZGDEAMS8pzCawq8e5MFFXTdAoMWOiram0dkRSVnLe2YOiArAFAtaAaH5Cjn61pq6NQTcsgZ05RrtiIfL88ummkutvgYGh-a7ejjZN82UxzRzaNNzYRuZ4PPU25sGJp9LBiKt2NTdpjsHufiXVNs2mLJT8njjR0zPrt7j8mX9-efTy_aq08fLk9Prlon-bq0HDXDAaxiSvdCDHxgg-QSe-EkDAC17gZgkirpNr3T3cZpxGHNlNAcRM-Pybul737uJxxcdZTsaPbJTzZ9N9F68_dP8Duzjd-MYrIegdYGr-4apPh1xlzM5LPDcbQB45wN45WSmklV0ZcP0Os4p1DXM0zAWjPBf1Iv_nR0b-XXqStAF8ClmHPCzT1CwdzGaZY4TY3T3MZpbqpGPdA4v0RVl_Ljf5VsUeY6JWwx_Tb9b9EPwm60uw |
| CitedBy_id | crossref_primary_10_3390_biomedicines10051007 crossref_primary_10_3390_cancers16112138 crossref_primary_10_1186_s13000_024_01492_3 crossref_primary_10_1016_j_compbiomed_2024_109510 crossref_primary_10_1111_cas_15325 crossref_primary_10_1007_s11060_025_05032_x crossref_primary_10_1007_s10637_025_01578_9 crossref_primary_10_3390_medicina58040526 crossref_primary_10_3389_fimmu_2024_1427200 crossref_primary_10_1515_biol_2022_0023 crossref_primary_10_1016_j_ejmech_2023_115464 crossref_primary_10_1007_s40618_022_01960_x crossref_primary_10_3390_ph16060796 crossref_primary_10_3390_brainsci12080986 crossref_primary_10_3390_cancers13246274 crossref_primary_10_1042_BSR20230489 crossref_primary_10_1016_j_prp_2021_153445 crossref_primary_10_3389_fimmu_2023_1037945 crossref_primary_10_1093_bib_bbac451 crossref_primary_10_3390_ijms231911149 crossref_primary_10_1007_s10142_023_01217_7 crossref_primary_10_3389_fonc_2020_605737 crossref_primary_10_1007_s12672_025_01818_7 crossref_primary_10_1590_1678_9199_jvatitd_2024_0015 crossref_primary_10_1016_j_ejmech_2024_116925 crossref_primary_10_1016_j_dnarep_2024_103700 crossref_primary_10_3390_diagnostics12102383 crossref_primary_10_1038_s41598_022_22924_4 crossref_primary_10_3390_jcm11206065 crossref_primary_10_1021_acs_jproteome_5c00158 crossref_primary_10_3390_molecules30173485 crossref_primary_10_1093_jncics_pkac010 crossref_primary_10_3390_brainsci12111472 crossref_primary_10_3390_cancers16020247 crossref_primary_10_1007_s13402_022_00723_3 crossref_primary_10_1038_s41374_022_00741_7 crossref_primary_10_1002_hep_32424 crossref_primary_10_3390_cancers16162862 crossref_primary_10_1186_s41824_025_00248_6 crossref_primary_10_1002_1878_0261_70005 crossref_primary_10_1186_s12880_022_00865_8 crossref_primary_10_1007_s13577_025_01235_6 crossref_primary_10_1007_s00894_022_05409_z crossref_primary_10_3390_molecules28237699 crossref_primary_10_1002_cnr2_1799 crossref_primary_10_3390_cancers13133311 crossref_primary_10_1007_s00432_024_05823_1 crossref_primary_10_1007_s11302_023_09951_0 crossref_primary_10_3390_ijms25020724 crossref_primary_10_1155_2022_1803544 crossref_primary_10_1007_s00259_022_05817_6 crossref_primary_10_1038_s41698_025_00909_6 crossref_primary_10_1016_j_bbcan_2023_188913 crossref_primary_10_3390_cells11162518 crossref_primary_10_1017_cjn_2023_253 crossref_primary_10_31083_j_jin2205118 crossref_primary_10_3389_fcell_2021_717601 crossref_primary_10_1155_2022_8164756 crossref_primary_10_1073_pnas_2403862122 crossref_primary_10_1016_j_bioorg_2021_104942 crossref_primary_10_1093_nop_npad022 crossref_primary_10_1007_s43188_022_00125_5 crossref_primary_10_1016_j_cca_2022_07_001 crossref_primary_10_3390_antiox11112202 crossref_primary_10_1016_j_tranon_2025_102323 crossref_primary_10_3389_fcell_2021_693215 crossref_primary_10_3389_fonc_2022_871798 crossref_primary_10_1038_s41582_024_00967_7 crossref_primary_10_3390_ijms25053040 crossref_primary_10_1002_cbin_70005 crossref_primary_10_3390_medicina60101688 crossref_primary_10_1016_j_biomaterials_2023_122026 crossref_primary_10_3390_molecules29163939 crossref_primary_10_1080_14796694_2024_2429948 crossref_primary_10_1016_j_drup_2025_101228 crossref_primary_10_1155_2022_5261285 crossref_primary_10_1007_s11060_023_04521_1 crossref_primary_10_3390_brainsci13040542 crossref_primary_10_3390_cancers16112121 crossref_primary_10_3390_ijms25074091 crossref_primary_10_1016_j_wneu_2021_11_103 crossref_primary_10_1186_s40164_024_00512_8 crossref_primary_10_3389_fonc_2023_1139383 crossref_primary_10_3389_fnmol_2024_1509280 crossref_primary_10_1016_j_drup_2022_100821 crossref_primary_10_1158_0008_5472_CAN_20_3730 crossref_primary_10_1007_s11060_025_05183_x crossref_primary_10_1016_j_nbd_2023_106327 crossref_primary_10_1055_s_0044_1789592 crossref_primary_10_1002_cam4_4683 crossref_primary_10_3389_fphar_2022_982424 crossref_primary_10_1155_2020_1872962 crossref_primary_10_1515_revneuro_2024_0054 crossref_primary_10_3389_fcell_2022_902298 crossref_primary_10_1007_s11517_023_02875_2 crossref_primary_10_1158_1078_0432_CCR_23_3241 crossref_primary_10_1016_j_ejmech_2025_117924 crossref_primary_10_1128_spectrum_02823_22 crossref_primary_10_1007_s10637_023_01373_4 crossref_primary_10_1212_WNL_0000000000209688 crossref_primary_10_1016_j_molmed_2021_12_008 crossref_primary_10_1038_s41416_023_02446_0 crossref_primary_10_4236_jbm_2025_138028 crossref_primary_10_1080_14796694_2025_2511587 crossref_primary_10_1097_MS9_0000000000003172 crossref_primary_10_3389_fimmu_2024_1327898 crossref_primary_10_4103_glioma_glioma_26_22 crossref_primary_10_1016_j_molmed_2024_02_004 crossref_primary_10_1016_j_tranon_2020_100819 crossref_primary_10_1016_j_lfs_2024_123174 crossref_primary_10_3390_cancers15184628 crossref_primary_10_1016_j_tig_2023_02_009 crossref_primary_10_1038_s41598_025_97067_3 crossref_primary_10_1002_med_21976 crossref_primary_10_1002_mrm_30561 crossref_primary_10_3390_biomedicines12102287 crossref_primary_10_3390_cancers13092107 crossref_primary_10_3390_molecules25204641 crossref_primary_10_2147_CMAR_S266533 crossref_primary_10_1002_anbr_202400107 crossref_primary_10_1007_s11010_024_04943_z crossref_primary_10_3171_2021_11_FOCUS21604 crossref_primary_10_1021_acs_jmedchem_5c00584 crossref_primary_10_1007_s00281_022_00976_y crossref_primary_10_1007_s10143_023_02169_z crossref_primary_10_1007_s00259_023_06562_0 crossref_primary_10_3389_fradi_2025_1546069 crossref_primary_10_1097_HM9_0000000000000160 crossref_primary_10_1186_s12943_022_01668_9 crossref_primary_10_3390_biomedicines13061298 crossref_primary_10_3390_ijms25168953 crossref_primary_10_1007_s00234_023_03196_9 crossref_primary_10_26508_lsa_202402924 crossref_primary_10_1016_j_media_2024_103435 crossref_primary_10_1038_s41419_024_06764_w crossref_primary_10_1002_adfm_202316386 crossref_primary_10_1016_j_lfs_2024_123018 crossref_primary_10_3389_fimmu_2025_1577920 crossref_primary_10_1016_j_crad_2023_09_025 crossref_primary_10_1002_adtp_202300197 crossref_primary_10_1007_s00330_025_11704_z crossref_primary_10_3390_ijms251910428 crossref_primary_10_1038_s41388_023_02738_y crossref_primary_10_2147_JIR_S517105 crossref_primary_10_3390_cancers16152752 crossref_primary_10_3390_diagnostics15101230 crossref_primary_10_1021_acsnano_5c09310 crossref_primary_10_1002_cam4_70016 crossref_primary_10_1186_s40478_024_01874_0 crossref_primary_10_1186_s12885_024_11970_y crossref_primary_10_3389_fimmu_2024_1523034 crossref_primary_10_3390_genes15091160 crossref_primary_10_1016_j_bbcan_2024_189102 crossref_primary_10_3390_diagnostics11020342 crossref_primary_10_3390_jcm14072518 crossref_primary_10_3389_fonc_2021_652133 crossref_primary_10_1007_s12672_024_01402_5 crossref_primary_10_3390_ijms23116042 crossref_primary_10_1200_EDBK_433640 crossref_primary_10_3390_ijms21197396 crossref_primary_10_1016_j_semcancer_2022_10_005 crossref_primary_10_1021_acs_jproteome_4c01129 crossref_primary_10_3390_biology13110885 crossref_primary_10_1016_j_jocn_2021_12_011 crossref_primary_10_1007_s11042_020_10487_3 crossref_primary_10_1016_j_bbcan_2023_189059 crossref_primary_10_1186_s13059_024_03436_y crossref_primary_10_1038_s41392_025_02299_4 crossref_primary_10_1007_s11864_024_01182_8 crossref_primary_10_3390_jpm11040290 crossref_primary_10_1155_2024_6565925 crossref_primary_10_3390_brainsci12060767 crossref_primary_10_1186_s12967_023_04498_5 crossref_primary_10_3389_fcell_2021_695351 crossref_primary_10_3389_fendo_2021_731096 crossref_primary_10_3389_fonc_2021_621432 crossref_primary_10_1007_s12672_025_02912_6 crossref_primary_10_1038_s41598_021_04214_7 crossref_primary_10_3390_ph16050726 crossref_primary_10_3390_metabo15050295 crossref_primary_10_1038_s41416_023_02324_9 crossref_primary_10_1038_s41598_024_56102_5 crossref_primary_10_1158_1078_0432_CCR_24_1814 crossref_primary_10_3389_fonc_2024_1515538 crossref_primary_10_3390_cancers16081516 crossref_primary_10_3390_antiox12020220 crossref_primary_10_2217_imt_2023_0027 crossref_primary_10_3390_metabo12111054 crossref_primary_10_3390_ijms222111421 crossref_primary_10_1101_gad_350693_123 crossref_primary_10_1007_s11060_022_04202_5 crossref_primary_10_1016_j_brainresbull_2021_11_016 crossref_primary_10_1002_prp2_70160 crossref_primary_10_3389_fonc_2023_1141851 crossref_primary_10_3389_fnmol_2025_1662414 crossref_primary_10_3390_ijms222413635 crossref_primary_10_1088_2057_1976_ad7593 crossref_primary_10_1007_s10143_025_03747_z crossref_primary_10_3390_ijms22115518 crossref_primary_10_3390_pharmaceutics17020142 crossref_primary_10_1007_s00428_023_03632_4 crossref_primary_10_3171_2021_11_FOCUS21587 crossref_primary_10_3390_ijms22158248 crossref_primary_10_1007_s11060_023_04486_1 crossref_primary_10_1097_MD_0000000000030643 crossref_primary_10_3389_fpubh_2022_898270 crossref_primary_10_1007_s11060_020_03673_8 crossref_primary_10_3390_diagnostics13152604 crossref_primary_10_1038_s41698_021_00173_4 crossref_primary_10_3390_diagnostics13172791 crossref_primary_10_1007_s11912_024_01602_w crossref_primary_10_3390_biomedicines10010001 crossref_primary_10_1038_s41598_024_77044_y crossref_primary_10_3389_fneur_2022_857825 crossref_primary_10_3389_fimmu_2022_1013542 crossref_primary_10_1186_s13046_023_02639_8 crossref_primary_10_3390_ijms23105351 crossref_primary_10_2147_IJN_S410080 crossref_primary_10_3390_ijms23168835 crossref_primary_10_1158_1078_0432_CCR_24_1056 crossref_primary_10_3389_fimmu_2022_865020 crossref_primary_10_35848_1882_0786_adac29 crossref_primary_10_1016_j_jneuroim_2025_578570 crossref_primary_10_3390_cancers15153924 crossref_primary_10_3390_medicina59111918 crossref_primary_10_1080_02688697_2021_2024144 crossref_primary_10_1016_j_crad_2025_106866 crossref_primary_10_1016_j_wneu_2023_06_099 crossref_primary_10_3390_biomedicines11030654 crossref_primary_10_1016_j_ultrasmedbio_2024_11_007 crossref_primary_10_1007_s12035_022_02739_0 crossref_primary_10_3389_fonc_2022_736177 crossref_primary_10_3390_jpm10030128 crossref_primary_10_1016_j_bbcan_2021_188616 crossref_primary_10_1177_19714009221098369 crossref_primary_10_1186_s13045_025_01710_5 crossref_primary_10_1186_s13046_021_02054_x crossref_primary_10_1002_jbio_202200291 crossref_primary_10_1007_s00415_023_11600_w crossref_primary_10_1016_j_heliyon_2024_e29897 crossref_primary_10_3389_fonc_2025_1569548 crossref_primary_10_1080_08916934_2022_2076085 crossref_primary_10_3390_molecules28072890 crossref_primary_10_3892_ol_2023_13927 crossref_primary_10_1007_s00432_023_05603_3 crossref_primary_10_56618_2071_2693_2023_15_2_21 crossref_primary_10_3390_ijms25137038 crossref_primary_10_1038_s41598_025_06096_5 crossref_primary_10_3390_biomedicines8090294 crossref_primary_10_1038_s44276_024_00051_z crossref_primary_10_1007_s00432_023_05022_4 crossref_primary_10_1021_acs_nanolett_5c03459 crossref_primary_10_3389_fonc_2022_921083 crossref_primary_10_1111_jcmm_18555 crossref_primary_10_3390_ph17060682 crossref_primary_10_3389_fonc_2021_619300 crossref_primary_10_1002_cam4_71187 crossref_primary_10_3892_ol_2024_14511 crossref_primary_10_3390_dna5030043 crossref_primary_10_1007_s11910_023_01265_3 crossref_primary_10_1007_s12017_021_08691_x crossref_primary_10_3390_ijms23031711 crossref_primary_10_1002_path_5898 crossref_primary_10_12688_f1000research_126243_2 crossref_primary_10_32635_2176_9745_RBC_2024v70n4_4936 crossref_primary_10_12688_f1000research_126243_1 crossref_primary_10_1007_s11010_023_04891_0 crossref_primary_10_1016_j_phrs_2022_106529 crossref_primary_10_1002_ijc_33375 crossref_primary_10_1016_j_arr_2024_102600 crossref_primary_10_1002_jmri_28630 crossref_primary_10_3390_cancers15020482 crossref_primary_10_1016_j_foodres_2023_113770 crossref_primary_10_1016_j_jocn_2025_111150 crossref_primary_10_1186_s40659_024_00512_2 crossref_primary_10_3389_fncel_2023_1288918 crossref_primary_10_3390_cancers17132178 crossref_primary_10_1111_pin_13308 crossref_primary_10_3390_biomedicines10040806 crossref_primary_10_3390_brainsci11070884 crossref_primary_10_1038_s41598_023_30413_5 crossref_primary_10_3390_medicina61040697 crossref_primary_10_1016_j_medj_2023_10_001 crossref_primary_10_3390_cancers14112602 crossref_primary_10_1016_j_ejrad_2023_110721 crossref_primary_10_1002_jmri_28663 crossref_primary_10_1007_s13402_021_00623_y crossref_primary_10_1186_s12915_024_02075_w crossref_primary_10_3390_cancers16244149 crossref_primary_10_1186_s12974_024_03222_4 crossref_primary_10_1038_s41467_023_40575_5 crossref_primary_10_1007_s12325_021_01977_3 crossref_primary_10_3390_molecules25163754 crossref_primary_10_1016_j_molstruc_2023_135178 crossref_primary_10_1016_j_intimp_2024_112922 crossref_primary_10_3390_cells10123529 crossref_primary_10_3389_fonc_2023_1134109 crossref_primary_10_1093_molbev_msab112 crossref_primary_10_1016_j_medj_2023_06_002 crossref_primary_10_1158_0008_5472_CAN_22_3965 crossref_primary_10_1186_s12935_025_03721_1 crossref_primary_10_1007_s11060_021_03854_z crossref_primary_10_1016_j_peptides_2025_171354 crossref_primary_10_3390_ijms24129825 crossref_primary_10_1038_s41419_020_03196_0 crossref_primary_10_1016_j_pharmthera_2021_107922 crossref_primary_10_3174_ajnr_A8726 crossref_primary_10_1016_j_aquaculture_2024_741864 crossref_primary_10_1016_j_yexcr_2022_113077 crossref_primary_10_1038_s41698_024_00762_z crossref_primary_10_1186_s12957_022_02602_5 crossref_primary_10_1371_journal_pone_0257090 crossref_primary_10_3390_cancers13174299 crossref_primary_10_1155_2020_4630218 crossref_primary_10_1016_j_jmoldx_2022_12_001 crossref_primary_10_1515_cclm_2022_1016 crossref_primary_10_3389_fneur_2021_652931 crossref_primary_10_1016_j_compbiomed_2025_109869 crossref_primary_10_1002_advs_202205949 crossref_primary_10_1055_s_0041_1741061 crossref_primary_10_1186_s12920_021_00904_3 crossref_primary_10_3390_brainsci14030275 crossref_primary_10_1093_neuonc_noae207 crossref_primary_10_3390_cancers15030716 crossref_primary_10_1042_EBC20220008 crossref_primary_10_1002_ijc_34381 crossref_primary_10_12688_f1000research_129089_1 crossref_primary_10_3390_cells10082116 crossref_primary_10_1016_j_ejphar_2023_175537 crossref_primary_10_1515_oncologie_2024_0001 crossref_primary_10_1515_biol_2021_0039 crossref_primary_10_1038_s41598_025_15658_6 crossref_primary_10_1186_s12645_025_00317_2 crossref_primary_10_3390_biomedicines12040713 crossref_primary_10_1016_j_jocn_2021_01_019 crossref_primary_10_3389_fgene_2022_894865 crossref_primary_10_1007_s12032_022_01769_x crossref_primary_10_3390_cancers14164023 crossref_primary_10_1186_s13578_024_01218_4 crossref_primary_10_3390_cells13070632 crossref_primary_10_1002_cam4_4913 crossref_primary_10_3389_fonc_2023_1235191 crossref_primary_10_1177_17246008211052571 crossref_primary_10_1007_s11055_024_01675_x crossref_primary_10_1093_noajnl_vdaf028 crossref_primary_10_1002_1878_0261_13598 crossref_primary_10_3389_fonc_2022_897042 crossref_primary_10_1093_noajnl_vdaf140 crossref_primary_10_3389_fonc_2025_1530144 crossref_primary_10_1002_advs_202503360 crossref_primary_10_3390_cancers15051440 crossref_primary_10_1016_j_tranon_2024_102187 crossref_primary_10_3390_cancers15072024 crossref_primary_10_3390_ijms26094175 crossref_primary_10_1016_j_bcp_2022_115090 crossref_primary_10_3390_ijms23126787 crossref_primary_10_1186_s12885_022_09791_y crossref_primary_10_3390_biomedicines13092263 crossref_primary_10_1002_jmri_29695 crossref_primary_10_1093_noajnl_vdaf136 crossref_primary_10_3390_cancers14133249 crossref_primary_10_1016_j_apsb_2021_10_008 crossref_primary_10_1016_j_csbj_2022_06_058 crossref_primary_10_1016_j_apsb_2022_12_019 crossref_primary_10_1016_j_ebr_2022_100526 crossref_primary_10_1093_neuonc_noac194 crossref_primary_10_1111_cns_14218 crossref_primary_10_3390_cancers14051125 crossref_primary_10_1016_j_colsurfb_2025_114668 crossref_primary_10_1016_j_neumar_2025_100039 crossref_primary_10_1111_cge_14200 crossref_primary_10_1002_jmri_29202 crossref_primary_10_1093_noajnl_vdaf002 crossref_primary_10_3390_molecules26206112 crossref_primary_10_1007_s10528_024_10716_6 crossref_primary_10_1016_j_ctrv_2024_102747 crossref_primary_10_1016_j_bbabio_2021_148410 crossref_primary_10_1007_s00259_023_06515_7 crossref_primary_10_1038_s41573_025_01227_z crossref_primary_10_1186_s40478_025_02006_y crossref_primary_10_1186_s41016_023_00349_w crossref_primary_10_3390_biomedicines12122732 crossref_primary_10_3390_cells11162486 crossref_primary_10_3390_cancers15164061 crossref_primary_10_3390_biomedicines13071584 crossref_primary_10_2174_0115733947296461240312051407 crossref_primary_10_3389_fonc_2023_1166207 crossref_primary_10_3390_biomedicines8120574 crossref_primary_10_3390_cells13141209 crossref_primary_10_3390_medicina59061056 crossref_primary_10_1007_s11604_023_01450_x crossref_primary_10_1016_j_plaphy_2024_108978 crossref_primary_10_1016_j_pharmthera_2020_107664 crossref_primary_10_1016_j_yao_2023_01_006 crossref_primary_10_1186_s12957_022_02831_8 crossref_primary_10_1016_j_compbiomed_2024_108532 crossref_primary_10_1016_j_semcancer_2024_03_004 crossref_primary_10_1007_s11912_023_01410_8 crossref_primary_10_3389_fnmol_2022_910543 crossref_primary_10_1002_cnr2_2136 crossref_primary_10_3389_fgene_2021_675780 crossref_primary_10_1016_j_addr_2023_115024 crossref_primary_10_1007_s11356_022_22401_5 crossref_primary_10_1088_2053_1591_ac9e8f |
| Cites_doi | 10.1093/jnci/djy230 10.1158/0008-5472.CAN-19-0054 10.1016/j.ebiom.2018.01.016 10.1158/1541-7786.MCR-16-0141 10.1158/1535-7163.MCT-19-0103 10.1038/cr.2010.145 10.1038/s41598-019-45346-1 10.1007/s00401-017-1800-0 10.1038/s41467-017-00984-9 10.1038/nature16490 10.1038/s41598-017-14065-w 10.1007/s13277-014-2644-z 10.1083/jcb.41.2.521 10.1097/CCO.0b013e32834d816a 10.1007/s00726-016-2342-9 10.1007/s00401-010-0781-z 10.1158/0008-5472.CAN-16-2773 10.1038/nm0311-291 10.1007/s10495-013-0877-8 10.1038/nature08617 10.18632/oncotarget.15015 10.1056/NEJMoa0808710 10.1016/j.ccell.2015.11.006 10.1016/j.ccr.2010.11.015 10.1093/neuonc/not243 10.1158/2159-8290.CD-13-0572 10.1038/onc.2011.416 10.3390/cancers10020049 10.1093/neuonc/noy016 10.1182/blood-2013-03-491571 10.1056/NEJMoa1716984 10.1111/imcb.12225 10.1172/JCI90644 10.1016/j.ccr.2010.01.020 10.1016/j.celrep.2018.02.084 10.1016/j.celrep.2018.10.099 10.1146/annurev-cancerbio-041916-065808 10.18632/oncotarget.12944 10.1080/2162402X.2016.1196310 10.18632/oncotarget.3723 10.1126/science.1236062 10.1038/nrg1945 10.1016/j.cell.2018.08.038 10.1074/jbc.RA117.001385 10.1038/s41591-018-0095-6 10.1101/gr.132738.111 10.1634/theoncologist.2011-0386 10.1158/0008-5472.CAN-16-2263 10.1038/nrendo.2015.117 10.1007/s00109-019-01802-z 10.1158/1078-0432.CCR-13-3052 10.1016/j.cell.2015.12.028 10.18632/oncotarget.1412 10.1200/JCO.2018.36.15_suppl.2001 10.1080/09553000400007680 10.3389/fnmol.2018.00082 10.1172/JCI69741 10.1016/j.celrep.2018.03.133 10.1016/j.ccr.2010.12.014 10.1186/s13578-019-0309-8 10.1021/acs.chemrestox.7b00009 10.1200/JCO.2010.28.3762 10.1158/1078-0432.CCR-17-3406 10.18632/oncotarget.17106 10.1212/WNL.0b013e3181c34ace 10.1200/JCO.2018.36.15_suppl.2002 10.1021/bi00099a026 10.1074/jbc.M114.575183 10.1093/neuonc/noz207 10.1126/scitranslmed.aaq1427 10.1038/s41467-018-03905-6 10.1093/neuonc/noy146 10.1038/cdd.2015.38 10.1016/j.cell.2013.09.034 10.1016/j.nicl.2016.06.018 10.1158/0008-5472.CAN-14-0772-T 10.18632/oncotarget.26203 10.1016/j.tranon.2019.10.019 10.1038/nature10860 10.1007/s00401-013-1194-6 10.1021/acsmedchemlett.7b00421 10.1101/gad.217406.113 10.1007/s13277-014-1784-5 10.1126/science.1170944 10.1172/JCI80011 10.1101/gad.294991.116 10.1158/1078-0432.CCR-09-0715 10.18632/oncotarget.1408 10.1212/WNL.0b013e3181f96282 10.1073/pnas.1019393108 10.1186/s40478-014-0180-0 10.1038/nature10866 10.1093/neuonc/not064 10.1074/jbc.M404298200 10.1002/path.2913 10.1038/leu.2017.46 10.1038/nchembio.1416 10.1093/neuonc/nor207 10.1016/j.exphem.2013.12.001 10.1016/j.ccr.2010.03.017 10.1158/0008-5472.CAN-14-0924 10.1038/nature10898 10.1038/embor.2011.43 10.1073/pnas.0914433107 10.1042/bst0311441 10.1016/j.celrep.2015.11.029 10.1093/jnci/djq497 10.1016/j.pharmthera.2018.03.006 10.1073/pnas.1708914114 10.1186/s40170-018-0177-4 10.1038/nature04433 10.1158/0008-5472.CAN-17-1352 10.1158/0008-5472.CAN-17-2926 10.1007/s00401-017-1677-y 10.1038/s41588-018-0170-4 10.1158/0008-5472.CAN-14-3603 10.1038/nature13387 10.1074/jbc.M402260200 10.1038/s41588-017-0001-z 10.1038/nature12750 10.1158/0008-5472.CAN-10-1666 10.1038/bjc.2011.27 10.1158/0008-5472.CAN-09-4295 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Cancer Research UK 2020 The Author(s), under exclusive licence to Cancer Research UK 2020. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Cancer Research UK 2020 – notice: The Author(s), under exclusive licence to Cancer Research UK 2020. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7U9 7X7 7XB 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AN0 AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1038/s41416-020-0814-x |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection ProQuest Health & Medical Collection Medical Database Biological Science Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest Central Student CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-1827 |
| EndPage | 1589 |
| ExternalDocumentID | PMC7250901 32291392 10_1038_s41416_020_0814_x |
| Genre | Journal Article Research Support, N.I.H., Intramural Review |
| GroupedDBID | --- 0R~ 23N 36B 39C 4.4 406 53G 5GY 5RE 6J9 70F 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 AACDK AANZL AASML AATNV AAWTL AAYZH AAZLF ABAKF ABLJU ABOCM ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACPRK ACRQY ACZOJ ADBBV ADFRT ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMYLF AN0 AOIJS ASPBG AVWKF AXYYD AZFZN BAWUL BBNVY BENPR BHPHI BKEYQ BKKNO BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DNIVK DPUIP DU5 E3Z EAP EBLON EBS EE. EIOEI EMB ESX EX3 F5P FDQFY FEDTE FERAY FIGPU FRJ FSGXE FYUFA GX1 HCIFZ HMCUK HVGLF HYE HZ~ IH2 IWAJR JSO JZLTJ KQ8 M1P M7P NAO NAPCQ NQJWS O9- OK1 P2P PQQKQ PROAC PSQYO Q2X RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SWTZT TAOOD TBHMF TDRGL TR2 UKHRP W2D WH7 WOW ~02 -Q- AAFWJ AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFFHD AFHIU AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PQGLB .55 .GJ 3V. 8WZ A6W ABAWZ ABDBF ACUHS AI. B0M CAG CGR COF CUY CVF EAD EAS EBC EBD ECM EIF EJD EMK EMOBN EPL FIZPM J5H M41 NPM SV3 TUS UDS VH1 X7M Y6R ZGI ~8M 7TO 7U9 7XB 8FE 8FH 8FK AZQEC DWQXO GNUQQ H94 K9. LK8 PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c536t-3e92ed0a7279b44d3d2d535eb4c50d003d28d025175cfbc98fc9eed62749304b3 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 464 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000526251700003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0007-0920 1532-1827 |
| IngestDate | Tue Nov 04 01:54:21 EST 2025 Sun Nov 09 13:20:42 EST 2025 Sun Nov 30 04:11:16 EST 2025 Wed Feb 19 02:27:47 EST 2025 Tue Nov 18 22:35:15 EST 2025 Sat Nov 29 02:47:31 EST 2025 Fri Feb 21 02:39:37 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c536t-3e92ed0a7279b44d3d2d535eb4c50d003d28d025175cfbc98fc9eed62749304b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7250901 |
| PMID | 32291392 |
| PQID | 2406924357 |
| PQPubID | 41855 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7250901 proquest_miscellaneous_2390159257 proquest_journals_2406924357 pubmed_primary_32291392 crossref_primary_10_1038_s41416_020_0814_x crossref_citationtrail_10_1038_s41416_020_0814_x springer_journals_10_1038_s41416_020_0814_x |
| PublicationCentury | 2000 |
| PublicationDate | 2020-05-26 |
| PublicationDateYYYYMMDD | 2020-05-26 |
| PublicationDate_xml | – month: 05 year: 2020 text: 2020-05-26 day: 26 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | British journal of cancer |
| PublicationTitleAbbrev | Br J Cancer |
| PublicationTitleAlternate | Br J Cancer |
| PublicationYear | 2020 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Nobusawa, Watanabe, Kleihues, Ohgaki (CR8) 2009; 15 Philip, Yu, Silvis, Shin, Robinson, Robinson (CR113) 2018; 23 Unruh, Zewde, Buss, Drumm, Tran, Scholtens (CR37) 2019; 9 Chen, Han (CR96) 2015; 125 Mazor, Chesnelong, Pankov, Jalbert, Hong, Hayes (CR109) 2017; 114 Duncan, Barwick, Jin, Rago, Kapoor-Vazirani, Powell (CR42) 2012; 22 Dubbink, Taal, van Marion, Kros, van Heuvel, Bromberg (CR70) 2009; 73 Ohba, Mukherjee, See, Pieper (CR82) 2014; 74 Lu, Ward, Kapoor, Rohle, Turcan, Abdel-Wahab (CR45) 2012; 483 Chaturvedi, Araujo Cruz, Jyotsana, Sharma, Yun, Gorlich (CR90) 2013; 122 Amankulor, Kim, Arora, Kargl, Szulzewsky, Hanke (CR112) 2017; 31 Sulkowski, Sundaram, Oeck, Corso, Liu, Noorbakhsh (CR76) 2018; 50 Karpel-Massler, Ishida, Bianchetti, Zhang, Shu, Tsujiuchi (CR122) 2017; 8 Pellegatta, Valletta, Corbetta, Patane, Zucca, Riccardi Sirtori (CR101) 2015; 3 Tateishi, Wakimoto, Iafrate, Tanaka, Loebel, Lelic (CR81) 2015; 28 Khurshed, Molenaar, Lenting, Leenders, van Noorden (CR29) 2017; 8 Chaumeil, Radoul, Najac, Eriksson, Viswanath, Blough (CR31) 2016; 12 Paschka, Schlenk, Gaidzik, Habdank, Kronke, Bullinger (CR10) 2010; 28 Tiburcio, Xiao, Chai, Asper, Tripp, Gillespie (CR114) 2018; 9 Reitman, Jin, Karoly, Spasojevic, Yang, Kinzler (CR18) 2011; 108 Tiburcio, Xiao, Berg, Asper, Lyne, Zhang (CR115) 2018; 135 Ward, Patel, Wise, Abdel-Wahab, Bennett, Coller (CR13) 2010; 17 Noushmehr, Weisenberger, Diefes, Phillips, Pujara, Berman (CR35) 2010; 17 Koh, Lee, Son, Lee, Ryoo, Chang (CR1) 2004; 279 McBrayer, Mayers, DiNatale, Shi, Khanal, Chakraborty (CR25) 2018; 175 Wang, Zhang, Liu, Wang, Sun, Li (CR95) 2016; 5 Yamashita, da Costa Rosa, Borodovsky, Festuccia, Chan, Riggins (CR118) 2019; 21 Chowdhury, Yeoh, Tian, Hillringhaus, Bagg, Rose (CR44) 2011; 12 Tsukada, Fang, Erdjument-Bromage, Warren, Borchers, Tempst (CR38) 2006; 439 Tang, Fu, Liu, Yu, Cai, Yang (CR105) 2019 Reczek, Chandel (CR48) 2017; 1 1 Ward, Cross, Lu, Weigert, Abel-Wahab, Levine (CR14) 2012; 31 Le, Cooper, Gouw, Dinavahi, Maitra, Deck (CR27) 2010; 107 Chen, Bian, Tang, Fedeles, Singh, Humulock (CR73) 2017; 30 Lu, Liu, Pang, Pacak, Yang (CR79) 2018; 188 Ren, Zhao, Huang, Zheng, Li, He (CR93) 2019; 97 Koivunen, Lee, Duncan, Lopez, Lu, Ramkissoon (CR34) 2012; 483 Dixon, Stockwell (CR49) 2014; 10 Molenaar, Botman, Smits, Hira, van Lith, Stap (CR65) 2015; 75 Zhang, Pusch, Innes, Sidlauskas, Ellis, Lau (CR116) 2019; 79 Rohle, Popovici-Muller, Palaskas, Turcan, Grommes, Campos (CR57) 2013; 340 Christensen, Smith, Zheng, Koestler, Houseman, Marsit (CR36) 2011; 103 Kopinja, Sevilla, Levitan, Dai, Vanko, Spooner (CR119) 2017; 7 Seltzer, Bennett, Joshi, Gao, Thomas, Ferraris (CR24) 2010; 70 Losman, Kaelin (CR16) 2013; 27 Chesnelong, Chaumeil, Blough, Al-Najjar, Stechishin, Chan (CR30) 2014; 16 Shi, Sun, Shi, Zuo, Cui, Ni (CR52) 2015; 36 Koncar, Chu, Romick-Rosendale, Wells, Chan, Qi (CR125) 2017; 8 Xu, Yang, Liu, Yang, Wang, Kim (CR39) 2011; 19 Badur, Muthusamy, Parker, Ma, McBrayer, Cordes (CR2) 2018; 25 CR64 Borger, Tanabe, Fan, Lopez, Fantin, Straley (CR11) 2012; 17 Mellinghoff, Penas-Prado, Peters, Cloughesy, Burris, Maher (CR59) 2018; 36 Waitkus, Pirozzi, Moure, Diplas, Hansen, Carpenter (CR23) 2018; 78 Cai, Liu, Han, Yang (CR55) 2019; 9 Mu, Long, Yang, Jin, Tao, Ge (CR97) 2018; 11 Reitman, Duncan, Poteet, Winters, Yan, Gooden (CR26) 2014; 289 Lu, Kwintkiewicz, Liu, Tech, Frady, Su (CR75) 2017; 77 Kohanbash, Carrera, Shrivastav, Ahn, Jahan, Mazor (CR99) 2017; 127 Bunse, Pusch, Bunse, Sahm, Sanghvi, Friedrich (CR94) 2018; 24 Zhou, Liu, Zhang, Yu, Li, Song (CR117) 2019; 13 Tang, Fu, Liu, Yu, Cai, Yang (CR92) 2020; 19 Luchman, Chesnelong, Cairncross, Weiss (CR108) 2013; 15 Mohrenz, Antonietti, Pusch, Capper, Balss, Voigt (CR54) 2013; 18 Flavahan, Drier, Liau, Gillespie, Venteicher, Stemmer-Rachamimov (CR67) 2016; 529 Hartmann, Hentschel, Wick, Capper, Felsberg, Simon (CR71) 2010; 120 Luchman, Stechishin, Dang, Blough, Chesnelong, Kelly (CR107) 2012; 14 Viswanath, Radoul, Izquierdo-Garcia, Ong, Luchman, Cairncross (CR121) 2018; 78 Popovici-Muller, Lemieux, Artin, Saunders, Salituro, Travins (CR60) 2018; 9 Schumacher, Bunse, Pusch, Sahm, Wiestler, Quandt (CR100) 2014; 512 Zhao, Lin, Xu, Jiang, Zha, Wang (CR33) 2009; 324 Platten, Schilling, Bunse, Wick, Bunse, Riehl (CR102) 2018; 36 Hurley, Dean, Koshland, Stroud (CR5) 1991; 30 Matre, Velez, Jacamo, Qi, Su, Cai (CR88) 2016; 7 Dang, White, Gross, Bennett, Bittinger, Driggers (CR15) 2009; 462 Itsumi, Inoue, Elia, Murakami, Sasaki, Lind (CR50) 2015; 22 Prensner, Chinnaiyan (CR17) 2011; 17 Maus, Peters (CR22) 2017; 49 Wakimoto, Tanaka, Curry, Loebel, Zhao, Tateishi (CR120) 2014; 20 Pusch, Krausert, Fischer, Balss, Ott, Schrimpf (CR61) 2017; 133 Núñez, Mendez, Kadiyala, Alghamri, Savelieff, Garcia-Fabiani, Haase, Koschmann, Calinescu, Kamran, Saxena, Patel, Carney, Guo, Edwards, Ljungman, Qin, Sartor, Tagett, Venneti, Brosnan-Cashman, Meeker, Gorbunova, Zhao, Kremer, Zhang, Lyssiotis, Jones, Herting, Ross, Hambardzumyan, Hervey-Jumper, Figueroa, Lowenstein, Castro (CR83) 2019; 11 Elhammali, Ippolito, Collins, Crowley, Marasa, Piwnica-Worms (CR87) 2014; 4 Choi, Yu, Grimmer, Wahl, Chang, Costello (CR9) 2018; 20 Doherty, Cleveland (CR28) 2013; 123 Tateishi, Higuchi, Miller, Koerner, Lelic, Shankar (CR80) 2017; 77 Chaturvedi, Herbst, Pusch, Klett, Goparaju, Stichel (CR62) 2017; 31 Turcan, Fabius, Borodovsky, Pedraza, Brennan, Huse (CR68) 2013; 4 Suijker, Oosting, Koornneef, Struys, Salomons, Schaap (CR124) 2015; 6 Jiang, Zhao, Shi, Zhang, Chen, Ma (CR123) 2018; 293 Xu, Zhao, Xu, Peng, Huang, Arnold (CR6) 2004; 279 Borodovsky, Seltzer, Riggins (CR19) 2012; 24 Ceccarelli, Barthel, Malta, Sabedot, Salama, Murray (CR46) 2016; 164 Houillier, Wang, Kaloshi, Mokhtari, Guillevin, Laffaire (CR72) 2010; 75 Rover, Gevensleben, Dietrich, Bootz, Landsberg, Goltz (CR98) 2018; 28 Behrend, Henderson, Zwacka (CR47) 2003; 31 Cao, Lu, Liu, Zhou, Song, Zhang (CR78) 2019; 97 Garrett, Sperry, Braas, Yan, Le, Mottahedeh (CR89) 2018; 6 Brennan, Verhaak, McKenna, Campos, Noushmehr, Salama (CR103) 2013; 155 Hollinshead, Munford, Eales, Bardella, Li, Escribano-Gonzalez (CR56) 2018; 22 Wang, Wu, Ma, Zhang, Yao, Hoadley (CR74) 2015; 13 Piaskowski, Bienkowski, Stoczynska-Fidelus, Stawski, Sieruta, Szybka (CR110) 2011; 104 Yan, Parsons, Jin, McLendon, Rasheed, Yuan (CR7) 2009; 360 Grassian, Parker, Davidson, Divakaruni, Green, Zhang (CR20) 2014; 74 Gilbert, Liu, Neltner, Pu, Morris, Sunkara (CR53) 2014; 127 Yang, Zhong, Peng, Lai, Ding (CR111) 2010; 20 Ohka, Ito, Ranjit, Senga, Motomura, Motomura (CR21) 2014; 35 Victor, Malta, Seki, Lita, Dowdy, Celiku (CR32) 2019 Andronesi, Arrillaga-Romany, Ly, Bogner, Ratai, Reitz (CR91) 2018; 9 Leighton, Poole, Lazarow, De Duve (CR4) 1969; 41 Pang, Lu, Caisova, Liu, Bullova, Huynh (CR77) 2018; 24 McEllin, Camacho, Mukherjee, Hahm, Tomimatsu, Bachoo (CR104) 2010; 70 Borodovsky, Salmasi, Turcan, Fabius, Baia, Eberhart (CR69) 2013; 4 Garten, Schuster, Penke, Gorski, de Giorgis, Kiess (CR84) 2015; 11 Amary, Bacsi, Maggiani, Damato, Halai, Berisha (CR12) 2011; 224 Kohli, Zhang (CR40) 2013; 502 Turcan, Rohle, Goenka, Walsh, Fang, Yilmaz (CR41) 2012; 483 Turcan, Makarov, Taranda, Wang, Fabius, Wu (CR43) 2018; 50 Johannessen, Mukherjee, Viswanath, Ohba, Ronen, Bjerkvig (CR63) 2016; 14 Madala, Punganuru, Arutla, Misra, Thomas, Srivenugopal (CR85) 2018; 10 Liu, Lu, Celiku, Li, Wu, Zhou (CR51) 2019; 111 Lee, Jo, Lee, Koh, Song, Park (CR3) 2004; 80 Klose, Kallin, Zhang (CR106) 2006; 7 Figueroa, Abdel-Wahab, Lu, Ward, Patel, Shih (CR66) 2010; 18 DiNardo, Stein, de Botton, Roboz, Altman, Mims (CR58) 2018; 378 Emadi, Jun, Tsukamoto, Fathi, Minden, Dang (CR86) 2014; 42 A Chaturvedi (814_CR62) 2017; 31 Y Lu (814_CR75) 2017; 77 IK Mellinghoff (814_CR59) 2018; 36 P Paschka (814_CR10) 2010; 28 Felipe J. Núñez (814_CR83) 2019; 11 M Garrett (814_CR89) 2018; 6 M Platten (814_CR102) 2018; 36 T Schumacher (814_CR100) 2014; 512 F Leighton (814_CR4) 1969; 41 MS Waitkus (814_CR23) 2018; 78 SH Lee (814_CR3) 2004; 80 Z Wang (814_CR95) 2016; 5 KER Hollinshead (814_CR56) 2018; 22 B Yang (814_CR111) 2010; 20 DR Borger (814_CR11) 2012; 17 D Unruh (814_CR37) 2019; 9 C Hartmann (814_CR71) 2010; 120 A Emadi (814_CR86) 2014; 42 A Borodovsky (814_CR19) 2012; 24 X Cao (814_CR78) 2019; 97 RJ Klose (814_CR106) 2006; 7 PDB Tiburcio (814_CR115) 2018; 135 B Jiang (814_CR123) 2018; 293 F Ohka (814_CR21) 2014; 35 IV Mohrenz (814_CR54) 2013; 18 HA Luchman (814_CR107) 2012; 14 S Turcan (814_CR43) 2018; 50 Y Lu (814_CR79) 2018; 188 X Tang (814_CR105) 2019 MR Gilbert (814_CR53) 2014; 127 G Kohanbash (814_CR99) 2017; 127 A Chaturvedi (814_CR90) 2013; 122 RJ Molenaar (814_CR65) 2015; 75 HA Luchman (814_CR108) 2013; 15 RM Kohli (814_CR40) 2013; 502 H Noushmehr (814_CR35) 2010; 17 TA Johannessen (814_CR63) 2016; 14 X Xu (814_CR6) 2004; 279 ZJ Reitman (814_CR26) 2014; 289 A Maus (814_CR22) 2017; 49 MM Chaumeil (814_CR31) 2016; 12 LK Rover (814_CR98) 2018; 28 H Yan (814_CR7) 2009; 360 JR Prensner (814_CR17) 2011; 17 L Dang (814_CR15) 2009; 462 HJ Dubbink (814_CR70) 2009; 73 RF Koncar (814_CR125) 2017; 8 S Pellegatta (814_CR101) 2015; 3 M Khurshed (814_CR29) 2017; 8 OC Andronesi (814_CR91) 2018; 9 SK McBrayer (814_CR25) 2018; 175 D Rohle (814_CR57) 2013; 340 T Mazor (814_CR109) 2017; 114 P Viswanath (814_CR121) 2018; 78 K Tateishi (814_CR80) 2017; 77 S Zhao (814_CR33) 2009; 324 C Houillier (814_CR72) 2010; 75 X Tang (814_CR92) 2020; 19 J Suijker (814_CR124) 2015; 6 S Ohba (814_CR82) 2014; 74 PL Sulkowski (814_CR76) 2018; 50 A Le (814_CR27) 2010; 107 SJ Dixon (814_CR49) 2014; 10 P Matre (814_CR88) 2016; 7 C Chesnelong (814_CR30) 2014; 16 L Behrend (814_CR47) 2003; 31 R Chowdhury (814_CR44) 2011; 12 P Koivunen (814_CR34) 2012; 483 WA Flavahan (814_CR67) 2016; 529 PS Ward (814_CR14) 2012; 31 PS Ward (814_CR13) 2010; 17 MF Amary (814_CR12) 2011; 224 M Ceccarelli (814_CR46) 2016; 164 CD DiNardo (814_CR58) 2018; 378 CW Brennan (814_CR103) 2013; 155 K Tateishi (814_CR81) 2015; 28 J Kopinja (814_CR119) 2017; 7 Y Zhou (814_CR117) 2019; 13 H Wakimoto (814_CR120) 2014; 20 B Philip (814_CR113) 2018; 23 HJ Koh (814_CR1) 2004; 279 S Pusch (814_CR61) 2017; 133 Y Pang (814_CR77) 2018; 24 G Karpel-Massler (814_CR122) 2017; 8 A Garten (814_CR84) 2015; 11 L Chen (814_CR96) 2015; 125 NM Amankulor (814_CR112) 2017; 31 L Mu (814_CR97) 2018; 11 Hanumantha Madala (814_CR85) 2018; 10 JR Doherty (814_CR28) 2013; 123 B McEllin (814_CR104) 2010; 70 814_CR64 F Ren (814_CR93) 2019; 97 Y Zhang (814_CR116) 2019; 79 MG Badur (814_CR2) 2018; 25 JA Losman (814_CR16) 2013; 27 CG Duncan (814_CR42) 2012; 22 S Nobusawa (814_CR8) 2009; 15 SJ Cai (814_CR55) 2019; 9 MJ Seltzer (814_CR24) 2010; 70 J Popovici-Muller (814_CR60) 2018; 9 S Piaskowski (814_CR110) 2011; 104 Y Liu (814_CR51) 2019; 111 JH Hurley (814_CR5) 1991; 30 W Xu (814_CR39) 2011; 19 C Lu (814_CR45) 2012; 483 L Bunse (814_CR94) 2018; 24 P Wang (814_CR74) 2015; 13 PDB Tiburcio (814_CR114) 2018; 9 F Chen (814_CR73) 2017; 30 A Borodovsky (814_CR69) 2013; 4 A Elhammali (814_CR87) 2014; 4 RR Victor (814_CR32) 2019 Y Tsukada (814_CR38) 2006; 439 J Shi (814_CR52) 2015; 36 S Turcan (814_CR41) 2012; 483 BC Christensen (814_CR36) 2011; 103 ME Figueroa (814_CR66) 2010; 18 AR Grassian (814_CR20) 2014; 74 CR Reczek (814_CR48) 2017; 1 1 S Turcan (814_CR68) 2013; 4 M Itsumi (814_CR50) 2015; 22 AS Yamashita (814_CR118) 2019; 21 ZJ Reitman (814_CR18) 2011; 108 S Choi (814_CR9) 2018; 20 |
| References_xml | – volume: 111 start-page: 1033 year: 2019 end-page: 1041 ident: CR51 article-title: Targeting IDH1-mutated malignancies with NRF2 blockade publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djy230 – volume: 79 start-page: 4994 year: 2019 end-page: 5007 ident: CR116 article-title: Mutant IDH sensitizes gliomas to endoplasmic reticulum stress and triggers apoptosis via miR-183-mediated inhibition of semaphorin 3E publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-19-0054 – volume: 28 start-page: 97 year: 2018 end-page: 104 ident: CR98 article-title: PD-1 (PDCD1) promoter methylation is a prognostic factor in patients with diffuse lower-grade gliomas harboring isocitrate dehydrogenase (IDH) mutations publication-title: EBioMedicine doi: 10.1016/j.ebiom.2018.01.016 – volume: 14 start-page: 976 year: 2016 end-page: 983 ident: CR63 article-title: Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-16-0141 – volume: 19 start-page: 221 year: 2020 end-page: 230 ident: CR92 article-title: Blockade of glutathione metabolism in IDH1-mutated glioma publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-19-0103 – volume: 20 start-page: 1188 year: 2010 end-page: 1200 ident: CR111 article-title: Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H publication-title: Cell Res. doi: 10.1038/cr.2010.145 – volume: 9 year: 2019 ident: CR37 article-title: Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers publication-title: Sci. Rep. doi: 10.1038/s41598-019-45346-1 – volume: 135 start-page: 285 year: 2018 end-page: 298 ident: CR115 article-title: Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis publication-title: Acta Neuropathol. doi: 10.1007/s00401-017-1800-0 – volume: 8 year: 2017 ident: CR122 article-title: Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL publication-title: Nat. Commun. doi: 10.1038/s41467-017-00984-9 – volume: 529 start-page: 110 year: 2016 end-page: 114 ident: CR67 article-title: Insulator dysfunction and oncogene activation in IDH mutant gliomas publication-title: Nature doi: 10.1038/nature16490 – volume: 7 year: 2017 ident: CR119 article-title: A brain penetrant mutant IDH1 inhibitor provides in vivo survival benefit publication-title: Sci. Rep. doi: 10.1038/s41598-017-14065-w – volume: 36 start-page: 655 year: 2015 end-page: 662 ident: CR52 article-title: Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation publication-title: Tumour Biol. doi: 10.1007/s13277-014-2644-z – volume: 41 start-page: 521 year: 1969 end-page: 535 ident: CR4 article-title: The synthesis and turnover of rat liver peroxisomes. I. Fractionation of peroxisome proteins publication-title: J. Cell Biol. doi: 10.1083/jcb.41.2.521 – volume: 24 start-page: 83 year: 2012 end-page: 89 ident: CR19 article-title: Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2 publication-title: Curr. Opin. Oncol. doi: 10.1097/CCO.0b013e32834d816a – volume: 49 start-page: 21 year: 2017 end-page: 32 ident: CR22 article-title: Glutamate and alpha-ketoglutarate: key players in glioma metabolism publication-title: Amino Acids doi: 10.1007/s00726-016-2342-9 – volume: 120 start-page: 707 year: 2010 end-page: 718 ident: CR71 article-title: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas publication-title: Acta Neuropathol. doi: 10.1007/s00401-010-0781-z – volume: 77 start-page: 1709 year: 2017 end-page: 1718 ident: CR75 article-title: Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2773 – volume: 17 start-page: 291 year: 2011 end-page: 293 ident: CR17 article-title: Metabolism unhinged: IDH mutations in cancer publication-title: Nat. Med. doi: 10.1038/nm0311-291 – volume: 18 start-page: 1416 year: 2013 end-page: 1425 ident: CR54 article-title: Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death publication-title: Apoptosis doi: 10.1007/s10495-013-0877-8 – volume: 462 start-page: 739 year: 2009 end-page: 744 ident: CR15 article-title: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate publication-title: Nature doi: 10.1038/nature08617 – volume: 8 start-page: 15827 year: 2017 end-page: 15837 ident: CR125 article-title: PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas publication-title: Oncotarget doi: 10.18632/oncotarget.15015 – volume: 360 start-page: 765 year: 2009 end-page: 773 ident: CR7 article-title: IDH1 and IDH2 mutations in gliomas publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0808710 – volume: 28 start-page: 773 year: 2015 end-page: 784 ident: CR81 article-title: Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.11.006 – volume: 18 start-page: 553 year: 2010 end-page: 567 ident: CR66 article-title: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.11.015 – volume: 16 start-page: 686 year: 2014 end-page: 695 ident: CR30 article-title: Lactate dehydrogenase A silencing in IDH mutant gliomas publication-title: Neuro-Oncology doi: 10.1093/neuonc/not243 – volume: 4 start-page: 828 year: 2014 end-page: 839 ident: CR87 article-title: A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0572 – volume: 31 start-page: 2491 year: 2012 end-page: 2498 ident: CR14 article-title: Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production publication-title: Oncogene doi: 10.1038/onc.2011.416 – volume: 10 start-page: 49 issue: 2 year: 2018 ident: CR85 article-title: Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies publication-title: Cancers doi: 10.3390/cancers10020049 – volume: 20 start-page: 1300 year: 2018 end-page: 1309 ident: CR9 article-title: Temozolomide-associated hypermutation in gliomas publication-title: Neuro-Oncology doi: 10.1093/neuonc/noy016 – volume: 122 start-page: 2877 year: 2013 end-page: 2887 ident: CR90 article-title: Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML publication-title: Blood doi: 10.1182/blood-2013-03-491571 – volume: 378 start-page: 2386 year: 2018 end-page: 2398 ident: CR58 article-title: Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1716984 – volume: 97 start-page: 457 year: 2019 end-page: 469 ident: CR93 article-title: The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas publication-title: Immunol. Cell Biol. doi: 10.1111/imcb.12225 – volume: 127 start-page: 1425 year: 2017 end-page: 1437 ident: CR99 article-title: Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas publication-title: J. Clin. Invest. doi: 10.1172/JCI90644 – volume: 17 start-page: 225 year: 2010 end-page: 234 ident: CR13 article-title: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.01.020 – volume: 22 start-page: 3107 year: 2018 end-page: 3114 ident: CR56 article-title: Oncogenic IDH1 mutations promote enhanced proline synthesis through PYCR1 to support the maintenance of mitochondrial redox homeostasis publication-title: Cell Rep. doi: 10.1016/j.celrep.2018.02.084 – volume: 25 start-page: 1018.e4 year: 2018 end-page: 1026.e4 ident: CR2 article-title: Oncogenic R132 IDH1 mutations limit NADPH for de novo lipogenesis through (D)2-hydroxyglutarate production in fibrosarcoma sells publication-title: Cell Rep. doi: 10.1016/j.celrep.2018.10.099 – volume: 1 1 start-page: 79 year: 2017 end-page: 98 ident: CR48 article-title: The two faces of reactive oxygen species in cancer publication-title: Annu. Rev. Cancer Biol. doi: 10.1146/annurev-cancerbio-041916-065808 – volume: 7 start-page: 79722 year: 2016 end-page: 79735 ident: CR88 article-title: Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes publication-title: Oncotarget doi: 10.18632/oncotarget.12944 – volume: 5 start-page: e1196310 year: 2016 ident: CR95 article-title: Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma publication-title: Oncoimmunology doi: 10.1080/2162402X.2016.1196310 – volume: 6 start-page: 12505 year: 2015 end-page: 12519 ident: CR124 article-title: Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines publication-title: Oncotarget doi: 10.18632/oncotarget.3723 – volume: 340 start-page: 626 year: 2013 end-page: 630 ident: CR57 article-title: An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells publication-title: Science doi: 10.1126/science.1236062 – volume: 7 start-page: 715 year: 2006 end-page: 727 ident: CR106 article-title: JmjC-domain-containing proteins and histone demethylation publication-title: Nat. Rev. Genet. doi: 10.1038/nrg1945 – volume: 175 start-page: 101 year: 2018 end-page: 116 e125 ident: CR25 article-title: Transaminase inhibition by 2-hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma publication-title: Cell doi: 10.1016/j.cell.2018.08.038 – volume: 293 start-page: 9747 year: 2018 end-page: 9758 ident: CR123 article-title: IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53 publication-title: J. Biol. Chem. doi: 10.1074/jbc.RA117.001385 – volume: 24 start-page: 1192 year: 2018 end-page: 1203 ident: CR94 article-title: Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate publication-title: Nat. Med. doi: 10.1038/s41591-018-0095-6 – volume: 22 start-page: 2339 year: 2012 end-page: 2355 ident: CR42 article-title: A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation publication-title: Genome Res. doi: 10.1101/gr.132738.111 – volume: 17 start-page: 72 year: 2012 end-page: 79 ident: CR11 article-title: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping publication-title: Oncologist doi: 10.1634/theoncologist.2011-0386 – volume: 77 start-page: 4102 year: 2017 end-page: 4115 ident: CR80 article-title: The alkylating chemotherapeutic temozolomide induces metabolic stress in IDH1-mutant cancers and potentiates NAD(+) depletion-mediated cytotoxicity publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2263 – volume: 11 start-page: 535 year: 2015 end-page: 546 ident: CR84 article-title: Physiological and pathophysiological roles of NAMPT and NAD metabolism publication-title: Nat. Rev. Endocrinol. doi: 10.1038/nrendo.2015.117 – volume: 97 start-page: 1183 year: 2019 end-page: 1193 ident: CR78 article-title: Combination of PARP inhibitor and temozolomide to suppress chordoma progression publication-title: J. Mol. Med. (Berl.) doi: 10.1007/s00109-019-01802-z – volume: 20 start-page: 2898 year: 2014 end-page: 2909 ident: CR120 article-title: Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-3052 – volume: 164 start-page: 550 year: 2016 end-page: 563 ident: CR46 article-title: Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma publication-title: Cell doi: 10.1016/j.cell.2015.12.028 – volume: 4 start-page: 1729 year: 2013 end-page: 1736 ident: CR68 article-title: Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine publication-title: Oncotarget doi: 10.18632/oncotarget.1412 – volume: 36 start-page: 2001 year: 2018 end-page: 2001 ident: CR102 article-title: A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: a first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.2001 – volume: 80 start-page: 635 year: 2004 end-page: 642 ident: CR3 article-title: Role of NADP+-dependent isocitrate dehydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by gamma-rays publication-title: Int. J. Radiat. Biol. doi: 10.1080/09553000400007680 – volume: 11 start-page: 82 year: 2018 ident: CR97 article-title: The IDH1 mutation-induced oncometabolite, 2-hydroxyglutarate, may affect DNA methylation and expression of PD-L1 in gliomas publication-title: Front Mol. Neurosci. doi: 10.3389/fnmol.2018.00082 – volume: 123 start-page: 3685 year: 2013 end-page: 3692 ident: CR28 article-title: Targeting lactate metabolism for cancer therapeutics publication-title: J. Clin. Invest. doi: 10.1172/JCI69741 – volume: 23 start-page: 1553 year: 2018 end-page: 1564 ident: CR113 article-title: Mutant IDH1 promotes glioma formation in vivo publication-title: Cell Rep. doi: 10.1016/j.celrep.2018.03.133 – volume: 19 start-page: 17 year: 2011 end-page: 30 ident: CR39 article-title: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.12.014 – volume: 9 start-page: 45 year: 2019 ident: CR55 article-title: Brusatol, an NRF2 inhibitor for future cancer therapeutic publication-title: Cell Biosci. doi: 10.1186/s13578-019-0309-8 – volume: 30 start-page: 1102 year: 2017 end-page: 1110 ident: CR73 article-title: Oncometabolites d- and l-2-hydroxyglutarate inhibit the AlkB family DNA repair enzymes under physiological conditions publication-title: Chem. Res. Toxicol. doi: 10.1021/acs.chemrestox.7b00009 – volume: 28 start-page: 3636 year: 2010 end-page: 3643 ident: CR10 article-title: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.28.3762 – volume: 24 start-page: 3423 year: 2018 end-page: 3432 ident: CR77 article-title: Targeting NAD(+)/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-3406 – volume: 8 start-page: 49165 year: 2017 end-page: 49177 ident: CR29 article-title: In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma publication-title: Oncotarget doi: 10.18632/oncotarget.17106 – volume: 73 start-page: 1792 year: 2009 end-page: 1795 ident: CR70 article-title: IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide publication-title: Neurology doi: 10.1212/WNL.0b013e3181c34ace – volume: 36 start-page: 2002 year: 2018 end-page: 2002 ident: CR59 article-title: Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.2002 – volume: 30 start-page: 8671 year: 1991 end-page: 8678 ident: CR5 article-title: Catalytic mechanism of NADP(+)-dependent isocitrate dehydrogenase: implications from the structures of magnesium-isocitrate and NADP+ complexes publication-title: Biochemistry doi: 10.1021/bi00099a026 – volume: 289 start-page: 23318 year: 2014 end-page: 23328 ident: CR26 article-title: Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and D-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia publication-title: J. Biol. Chem. doi: 10.1074/jbc.M114.575183 – year: 2019 ident: CR32 article-title: Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas publication-title: Neuro-Oncology doi: 10.1093/neuonc/noz207 – volume: 11 start-page: eaaq1427 issue: 479 year: 2019 ident: CR83 article-title: IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response publication-title: Science Translational Medicine doi: 10.1126/scitranslmed.aaq1427 – volume: 9 year: 2018 ident: CR91 article-title: Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate publication-title: Nat. Commun. doi: 10.1038/s41467-018-03905-6 – volume: 21 start-page: 189 year: 2019 end-page: 200 ident: CR118 article-title: Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide publication-title: Neuro-Oncology doi: 10.1093/neuonc/noy146 – volume: 22 start-page: 1837 year: 2015 end-page: 1845 ident: CR50 article-title: Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP(+)/NADPH ratio publication-title: Cell Death Differ. doi: 10.1038/cdd.2015.38 – volume: 155 start-page: 462 year: 2013 end-page: 477 ident: CR103 article-title: The somatic genomic landscape of glioblastoma publication-title: Cell doi: 10.1016/j.cell.2013.09.034 – volume: 12 start-page: 180 year: 2016 end-page: 189 ident: CR31 article-title: Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: implications for diagnosis and response monitoring publication-title: Neuroimage Clin. doi: 10.1016/j.nicl.2016.06.018 – volume: 74 start-page: 3317 year: 2014 end-page: 3331 ident: CR20 article-title: IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-0772-T – volume: 9 start-page: 35100 year: 2018 end-page: 35113 ident: CR114 article-title: IDH1(R132H) is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment publication-title: Oncotarget doi: 10.18632/oncotarget.26203 – volume: 13 start-page: 125 year: 2019 end-page: 134 ident: CR117 article-title: Autocrine BMP4 signaling enhances tumor aggressiveness via promoting Wnt/beta-Catenin signaling in IDH1-mutant gliomas publication-title: Transl. Oncol. doi: 10.1016/j.tranon.2019.10.019 – volume: 483 start-page: 474 year: 2012 end-page: 478 ident: CR45 article-title: IDH mutation impairs histone demethylation and results in a block to cell differentiation publication-title: Nature doi: 10.1038/nature10860 – volume: 127 start-page: 221 year: 2014 end-page: 233 ident: CR53 article-title: Autophagy and oxidative stress in gliomas with IDH1 mutations publication-title: Acta Neuropathol. doi: 10.1007/s00401-013-1194-6 – volume: 9 start-page: 300 year: 2018 end-page: 305 ident: CR60 article-title: Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers publication-title: ACS Med. Chem. Lett. doi: 10.1021/acsmedchemlett.7b00421 – volume: 27 start-page: 836 year: 2013 end-page: 852 ident: CR16 article-title: What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer publication-title: Genes Dev. doi: 10.1101/gad.217406.113 – volume: 35 start-page: 5911 year: 2014 end-page: 5920 ident: CR21 article-title: Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation publication-title: Tumour Biol. doi: 10.1007/s13277-014-1784-5 – volume: 324 start-page: 261 year: 2009 end-page: 265 ident: CR33 article-title: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha publication-title: Science doi: 10.1126/science.1170944 – volume: 125 start-page: 3384 year: 2015 end-page: 3391 ident: CR96 article-title: Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future publication-title: J. Clin. Invest. doi: 10.1172/JCI80011 – volume: 31 start-page: 774 year: 2017 end-page: 786 ident: CR112 article-title: Mutant IDH1 regulates the tumor-associated immune system in gliomas publication-title: Genes Dev. doi: 10.1101/gad.294991.116 – volume: 15 start-page: 6002 year: 2009 end-page: 6007 ident: CR8 article-title: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-0715 – volume: 4 start-page: 1737 year: 2013 end-page: 1747 ident: CR69 article-title: 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft publication-title: Oncotarget doi: 10.18632/oncotarget.1408 – ident: CR64 – volume: 75 start-page: 1560 year: 2010 end-page: 1566 ident: CR72 article-title: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas publication-title: Neurology doi: 10.1212/WNL.0b013e3181f96282 – volume: 108 start-page: 3270 year: 2011 end-page: 3275 ident: CR18 article-title: Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1019393108 – volume: 3 start-page: 4 year: 2015 ident: CR101 article-title: Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma publication-title: Acta Neuropathol. Commun. doi: 10.1186/s40478-014-0180-0 – volume: 483 start-page: 479 year: 2012 end-page: 483 ident: CR41 article-title: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype publication-title: Nature doi: 10.1038/nature10866 – volume: 15 start-page: 979 year: 2013 end-page: 980 ident: CR108 article-title: Spontaneous loss of heterozygosity leading to homozygous R132H in a patient-derived IDH1 mutant cell line publication-title: Neuro-Oncology doi: 10.1093/neuonc/not064 – volume: 279 start-page: 33946 year: 2004 end-page: 33957 ident: CR6 article-title: Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity publication-title: J. Biol. Chem. doi: 10.1074/jbc.M404298200 – volume: 224 start-page: 334 year: 2011 end-page: 343 ident: CR12 article-title: IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours publication-title: J. Pathol. doi: 10.1002/path.2913 – volume: 31 start-page: 2020 year: 2017 end-page: 2028 ident: CR62 article-title: Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo publication-title: Leukemia doi: 10.1038/leu.2017.46 – volume: 10 start-page: 9 year: 2014 end-page: 17 ident: CR49 article-title: The role of iron and reactive oxygen species in cell death publication-title: Nat. Chem. Biol. doi: 10.1038/nchembio.1416 – volume: 14 start-page: 184 year: 2012 end-page: 191 ident: CR107 article-title: An in vivo patient-derived model of endogenous IDH1-mutant glioma publication-title: Neuro-Oncology doi: 10.1093/neuonc/nor207 – volume: 42 start-page: 247 year: 2014 end-page: 251 ident: CR86 article-title: Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations publication-title: Exp. Hematol. doi: 10.1016/j.exphem.2013.12.001 – volume: 17 start-page: 510 year: 2010 end-page: 522 ident: CR35 article-title: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.03.017 – volume: 74 start-page: 4836 year: 2014 end-page: 4844 ident: CR82 article-title: Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-0924 – volume: 483 start-page: 484 year: 2012 end-page: 488 ident: CR34 article-title: Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation publication-title: Nature doi: 10.1038/nature10898 – volume: 12 start-page: 463 year: 2011 end-page: 469 ident: CR44 article-title: The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases publication-title: EMBO Rep. doi: 10.1038/embor.2011.43 – volume: 107 start-page: 2037 year: 2010 end-page: 2042 ident: CR27 article-title: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0914433107 – volume: 31 start-page: 1441 year: 2003 end-page: 1444 ident: CR47 article-title: Reactive oxygen species in oncogenic transformation publication-title: Biochem. Soc. Trans. doi: 10.1042/bst0311441 – volume: 13 start-page: 2353 year: 2015 end-page: 2361 ident: CR74 article-title: Oncometabolite D-2-hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents publication-title: Cell Rep. doi: 10.1016/j.celrep.2015.11.029 – volume: 103 start-page: 143 year: 2011 end-page: 153 ident: CR36 article-title: DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djq497 – volume: 188 start-page: 168 year: 2018 end-page: 175 ident: CR79 article-title: Double-barreled gun: combination of PARP inhibitor with conventional chemotherapy publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2018.03.006 – volume: 114 start-page: 10743 year: 2017 end-page: 10748 ident: CR109 article-title: Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1708914114 – volume: 6 start-page: 4 year: 2018 ident: CR89 article-title: Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities publication-title: Cancer Metab. doi: 10.1186/s40170-018-0177-4 – volume: 439 start-page: 811 year: 2006 end-page: 816 ident: CR38 article-title: Histone demethylation by a family of JmjC domain-containing proteins publication-title: Nature doi: 10.1038/nature04433 – volume: 78 start-page: 36 year: 2018 end-page: 50 ident: CR23 article-title: Adaptive evolution of the GDH2 allosteric domain promotes gliomagenesis by resolving IDH1(R132H)-induced metabolic liabilities publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-1352 – volume: 78 start-page: 2290 year: 2018 end-page: 2304 ident: CR121 article-title: 2-Hydroxyglutarate-mediated autophagy of the endoplasmic reticulum leads to an unusual downregulation of phospholipid biosynthesis in mutant IDH1 gliomas publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-2926 – volume: 133 start-page: 629 year: 2017 end-page: 644 ident: CR61 article-title: Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo publication-title: Acta Neuropathol. doi: 10.1007/s00401-017-1677-y – volume: 50 start-page: 1086 year: 2018 end-page: 1092 ident: CR76 article-title: Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair publication-title: Nat. Genet. doi: 10.1038/s41588-018-0170-4 – volume: 75 start-page: 4790 year: 2015 end-page: 4802 ident: CR65 article-title: Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant inhibitor AGI-5198 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-3603 – volume: 512 start-page: 324 year: 2014 end-page: 327 ident: CR100 article-title: A vaccine targeting mutant IDH1 induces antitumour immunity publication-title: Nature doi: 10.1038/nature13387 – volume: 279 start-page: 39968 year: 2004 end-page: 39974 ident: CR1 article-title: Cytosolic NADP+-dependent isocitrate dehydrogenase plays a key role in lipid metabolism publication-title: J. Biol. Chem. doi: 10.1074/jbc.M402260200 – volume: 50 start-page: 62 year: 2018 end-page: 72 ident: CR43 article-title: Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence publication-title: Nat. Genet. doi: 10.1038/s41588-017-0001-z – year: 2019 ident: CR105 article-title: Blockade of glutathione metabolism in IDH1-mutated glioma publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-19-0103 – volume: 502 start-page: 472 year: 2013 end-page: 479 ident: CR40 article-title: TET enzymes, TDG and the dynamics of DNA demethylation publication-title: Nature doi: 10.1038/nature12750 – volume: 70 start-page: 8981 year: 2010 end-page: 8987 ident: CR24 article-title: Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-1666 – volume: 104 start-page: 968 year: 2011 end-page: 970 ident: CR110 article-title: Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions publication-title: Br. J. Cancer doi: 10.1038/bjc.2011.27 – volume: 70 start-page: 5457 year: 2010 end-page: 5464 ident: CR104 article-title: PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-09-4295 – volume: 30 start-page: 1102 year: 2017 ident: 814_CR73 publication-title: Chem. Res. Toxicol. doi: 10.1021/acs.chemrestox.7b00009 – volume: 97 start-page: 1183 year: 2019 ident: 814_CR78 publication-title: J. Mol. Med. (Berl.) doi: 10.1007/s00109-019-01802-z – volume: 188 start-page: 168 year: 2018 ident: 814_CR79 publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2018.03.006 – volume: 18 start-page: 553 year: 2010 ident: 814_CR66 publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.11.015 – volume: 5 start-page: e1196310 year: 2016 ident: 814_CR95 publication-title: Oncoimmunology doi: 10.1080/2162402X.2016.1196310 – volume: 7 start-page: 79722 year: 2016 ident: 814_CR88 publication-title: Oncotarget doi: 10.18632/oncotarget.12944 – volume: 20 start-page: 1188 year: 2010 ident: 814_CR111 publication-title: Cell Res. doi: 10.1038/cr.2010.145 – volume: 70 start-page: 5457 year: 2010 ident: 814_CR104 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-09-4295 – volume: 25 start-page: 1018.e4 year: 2018 ident: 814_CR2 publication-title: Cell Rep. doi: 10.1016/j.celrep.2018.10.099 – volume: 279 start-page: 33946 year: 2004 ident: 814_CR6 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M404298200 – volume: 24 start-page: 83 year: 2012 ident: 814_CR19 publication-title: Curr. Opin. Oncol. doi: 10.1097/CCO.0b013e32834d816a – year: 2019 ident: 814_CR105 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-19-0103 – volume: 9 start-page: 45 year: 2019 ident: 814_CR55 publication-title: Cell Biosci. doi: 10.1186/s13578-019-0309-8 – volume: 155 start-page: 462 year: 2013 ident: 814_CR103 publication-title: Cell doi: 10.1016/j.cell.2013.09.034 – volume: 9 start-page: 300 year: 2018 ident: 814_CR60 publication-title: ACS Med. Chem. Lett. doi: 10.1021/acsmedchemlett.7b00421 – volume: 14 start-page: 976 year: 2016 ident: 814_CR63 publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-16-0141 – volume: 22 start-page: 3107 year: 2018 ident: 814_CR56 publication-title: Cell Rep. doi: 10.1016/j.celrep.2018.02.084 – volume: 41 start-page: 521 year: 1969 ident: 814_CR4 publication-title: J. Cell Biol. doi: 10.1083/jcb.41.2.521 – ident: 814_CR64 – volume: 8 year: 2017 ident: 814_CR122 publication-title: Nat. Commun. doi: 10.1038/s41467-017-00984-9 – volume: 30 start-page: 8671 year: 1991 ident: 814_CR5 publication-title: Biochemistry doi: 10.1021/bi00099a026 – volume: 127 start-page: 221 year: 2014 ident: 814_CR53 publication-title: Acta Neuropathol. doi: 10.1007/s00401-013-1194-6 – volume: 9 year: 2019 ident: 814_CR37 publication-title: Sci. Rep. doi: 10.1038/s41598-019-45346-1 – volume: 28 start-page: 97 year: 2018 ident: 814_CR98 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2018.01.016 – volume: 15 start-page: 979 year: 2013 ident: 814_CR108 publication-title: Neuro-Oncology doi: 10.1093/neuonc/not064 – volume: 20 start-page: 1300 year: 2018 ident: 814_CR9 publication-title: Neuro-Oncology doi: 10.1093/neuonc/noy016 – volume: 529 start-page: 110 year: 2016 ident: 814_CR67 publication-title: Nature doi: 10.1038/nature16490 – volume: 13 start-page: 125 year: 2019 ident: 814_CR117 publication-title: Transl. Oncol. doi: 10.1016/j.tranon.2019.10.019 – volume: 502 start-page: 472 year: 2013 ident: 814_CR40 publication-title: Nature doi: 10.1038/nature12750 – volume: 483 start-page: 474 year: 2012 ident: 814_CR45 publication-title: Nature doi: 10.1038/nature10860 – volume: 13 start-page: 2353 year: 2015 ident: 814_CR74 publication-title: Cell Rep. doi: 10.1016/j.celrep.2015.11.029 – volume: 16 start-page: 686 year: 2014 ident: 814_CR30 publication-title: Neuro-Oncology doi: 10.1093/neuonc/not243 – volume: 4 start-page: 1729 year: 2013 ident: 814_CR68 publication-title: Oncotarget doi: 10.18632/oncotarget.1412 – volume: 108 start-page: 3270 year: 2011 ident: 814_CR18 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1019393108 – volume: 164 start-page: 550 year: 2016 ident: 814_CR46 publication-title: Cell doi: 10.1016/j.cell.2015.12.028 – volume: 279 start-page: 39968 year: 2004 ident: 814_CR1 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M402260200 – volume: 111 start-page: 1033 year: 2019 ident: 814_CR51 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djy230 – volume: 24 start-page: 1192 year: 2018 ident: 814_CR94 publication-title: Nat. Med. doi: 10.1038/s41591-018-0095-6 – volume: 8 start-page: 15827 year: 2017 ident: 814_CR125 publication-title: Oncotarget doi: 10.18632/oncotarget.15015 – volume: 78 start-page: 36 year: 2018 ident: 814_CR23 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-1352 – volume: 42 start-page: 247 year: 2014 ident: 814_CR86 publication-title: Exp. Hematol. doi: 10.1016/j.exphem.2013.12.001 – volume: 27 start-page: 836 year: 2013 ident: 814_CR16 publication-title: Genes Dev. doi: 10.1101/gad.217406.113 – volume: 12 start-page: 463 year: 2011 ident: 814_CR44 publication-title: EMBO Rep. doi: 10.1038/embor.2011.43 – volume: 135 start-page: 285 year: 2018 ident: 814_CR115 publication-title: Acta Neuropathol. doi: 10.1007/s00401-017-1800-0 – volume: 36 start-page: 655 year: 2015 ident: 814_CR52 publication-title: Tumour Biol. doi: 10.1007/s13277-014-2644-z – volume: 378 start-page: 2386 year: 2018 ident: 814_CR58 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1716984 – volume: 35 start-page: 5911 year: 2014 ident: 814_CR21 publication-title: Tumour Biol. doi: 10.1007/s13277-014-1784-5 – volume: 78 start-page: 2290 year: 2018 ident: 814_CR121 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-2926 – volume: 24 start-page: 3423 year: 2018 ident: 814_CR77 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-3406 – volume: 104 start-page: 968 year: 2011 ident: 814_CR110 publication-title: Br. J. Cancer doi: 10.1038/bjc.2011.27 – volume: 125 start-page: 3384 year: 2015 ident: 814_CR96 publication-title: J. Clin. Invest. doi: 10.1172/JCI80011 – volume: 19 start-page: 221 year: 2020 ident: 814_CR92 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-19-0103 – volume: 107 start-page: 2037 year: 2010 ident: 814_CR27 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0914433107 – volume: 50 start-page: 1086 year: 2018 ident: 814_CR76 publication-title: Nat. Genet. doi: 10.1038/s41588-018-0170-4 – volume: 7 start-page: 715 year: 2006 ident: 814_CR106 publication-title: Nat. Rev. Genet. doi: 10.1038/nrg1945 – volume: 4 start-page: 828 year: 2014 ident: 814_CR87 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0572 – volume: 74 start-page: 3317 year: 2014 ident: 814_CR20 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-0772-T – volume: 70 start-page: 8981 year: 2010 ident: 814_CR24 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-1666 – volume: 483 start-page: 484 year: 2012 ident: 814_CR34 publication-title: Nature doi: 10.1038/nature10898 – volume: 120 start-page: 707 year: 2010 ident: 814_CR71 publication-title: Acta Neuropathol. doi: 10.1007/s00401-010-0781-z – volume: 103 start-page: 143 year: 2011 ident: 814_CR36 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djq497 – volume: 14 start-page: 184 year: 2012 ident: 814_CR107 publication-title: Neuro-Oncology doi: 10.1093/neuonc/nor207 – volume: 79 start-page: 4994 year: 2019 ident: 814_CR116 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-19-0054 – volume: 289 start-page: 23318 year: 2014 ident: 814_CR26 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M114.575183 – volume: 439 start-page: 811 year: 2006 ident: 814_CR38 publication-title: Nature doi: 10.1038/nature04433 – volume: 50 start-page: 62 year: 2018 ident: 814_CR43 publication-title: Nat. Genet. doi: 10.1038/s41588-017-0001-z – volume: 75 start-page: 4790 year: 2015 ident: 814_CR65 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-3603 – volume: 20 start-page: 2898 year: 2014 ident: 814_CR120 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-3052 – volume: 19 start-page: 17 year: 2011 ident: 814_CR39 publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.12.014 – volume: 31 start-page: 1441 year: 2003 ident: 814_CR47 publication-title: Biochem. Soc. Trans. doi: 10.1042/bst0311441 – volume: 127 start-page: 1425 year: 2017 ident: 814_CR99 publication-title: J. Clin. Invest. doi: 10.1172/JCI90644 – volume: 114 start-page: 10743 year: 2017 ident: 814_CR109 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1708914114 – volume: 77 start-page: 1709 year: 2017 ident: 814_CR75 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2773 – volume: 122 start-page: 2877 year: 2013 ident: 814_CR90 publication-title: Blood doi: 10.1182/blood-2013-03-491571 – volume: 73 start-page: 1792 year: 2009 ident: 814_CR70 publication-title: Neurology doi: 10.1212/WNL.0b013e3181c34ace – volume: 28 start-page: 773 year: 2015 ident: 814_CR81 publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.11.006 – volume: 49 start-page: 21 year: 2017 ident: 814_CR22 publication-title: Amino Acids doi: 10.1007/s00726-016-2342-9 – volume: 483 start-page: 479 year: 2012 ident: 814_CR41 publication-title: Nature doi: 10.1038/nature10866 – volume: 340 start-page: 626 year: 2013 ident: 814_CR57 publication-title: Science doi: 10.1126/science.1236062 – volume: 22 start-page: 1837 year: 2015 ident: 814_CR50 publication-title: Cell Death Differ. doi: 10.1038/cdd.2015.38 – volume: 17 start-page: 510 year: 2010 ident: 814_CR35 publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.03.017 – volume: 80 start-page: 635 year: 2004 ident: 814_CR3 publication-title: Int. J. Radiat. Biol. doi: 10.1080/09553000400007680 – volume: 18 start-page: 1416 year: 2013 ident: 814_CR54 publication-title: Apoptosis doi: 10.1007/s10495-013-0877-8 – volume: 11 start-page: eaaq1427 issue: 479 year: 2019 ident: 814_CR83 publication-title: Science Translational Medicine doi: 10.1126/scitranslmed.aaq1427 – volume: 9 year: 2018 ident: 814_CR91 publication-title: Nat. Commun. doi: 10.1038/s41467-018-03905-6 – volume: 462 start-page: 739 year: 2009 ident: 814_CR15 publication-title: Nature doi: 10.1038/nature08617 – volume: 7 year: 2017 ident: 814_CR119 publication-title: Sci. Rep. doi: 10.1038/s41598-017-14065-w – volume: 3 start-page: 4 year: 2015 ident: 814_CR101 publication-title: Acta Neuropathol. Commun. doi: 10.1186/s40478-014-0180-0 – volume: 97 start-page: 457 year: 2019 ident: 814_CR93 publication-title: Immunol. Cell Biol. doi: 10.1111/imcb.12225 – volume: 133 start-page: 629 year: 2017 ident: 814_CR61 publication-title: Acta Neuropathol. doi: 10.1007/s00401-017-1677-y – volume: 8 start-page: 49165 year: 2017 ident: 814_CR29 publication-title: Oncotarget doi: 10.18632/oncotarget.17106 – volume: 10 start-page: 9 year: 2014 ident: 814_CR49 publication-title: Nat. Chem. Biol. doi: 10.1038/nchembio.1416 – volume: 11 start-page: 82 year: 2018 ident: 814_CR97 publication-title: Front Mol. Neurosci. doi: 10.3389/fnmol.2018.00082 – volume: 23 start-page: 1553 year: 2018 ident: 814_CR113 publication-title: Cell Rep. doi: 10.1016/j.celrep.2018.03.133 – volume: 324 start-page: 261 year: 2009 ident: 814_CR33 publication-title: Science doi: 10.1126/science.1170944 – volume: 11 start-page: 535 year: 2015 ident: 814_CR84 publication-title: Nat. Rev. Endocrinol. doi: 10.1038/nrendo.2015.117 – volume: 293 start-page: 9747 year: 2018 ident: 814_CR123 publication-title: J. Biol. Chem. doi: 10.1074/jbc.RA117.001385 – volume: 31 start-page: 774 year: 2017 ident: 814_CR112 publication-title: Genes Dev. doi: 10.1101/gad.294991.116 – volume: 22 start-page: 2339 year: 2012 ident: 814_CR42 publication-title: Genome Res. doi: 10.1101/gr.132738.111 – volume: 75 start-page: 1560 year: 2010 ident: 814_CR72 publication-title: Neurology doi: 10.1212/WNL.0b013e3181f96282 – volume: 175 start-page: 101 year: 2018 ident: 814_CR25 publication-title: Cell doi: 10.1016/j.cell.2018.08.038 – volume: 36 start-page: 2001 year: 2018 ident: 814_CR102 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.2001 – volume: 1 1 start-page: 79 year: 2017 ident: 814_CR48 publication-title: Annu. Rev. Cancer Biol. doi: 10.1146/annurev-cancerbio-041916-065808 – volume: 9 start-page: 35100 year: 2018 ident: 814_CR114 publication-title: Oncotarget doi: 10.18632/oncotarget.26203 – volume: 17 start-page: 291 year: 2011 ident: 814_CR17 publication-title: Nat. Med. doi: 10.1038/nm0311-291 – volume: 31 start-page: 2491 year: 2012 ident: 814_CR14 publication-title: Oncogene doi: 10.1038/onc.2011.416 – volume: 360 start-page: 765 year: 2009 ident: 814_CR7 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0808710 – volume: 6 start-page: 4 year: 2018 ident: 814_CR89 publication-title: Cancer Metab. doi: 10.1186/s40170-018-0177-4 – volume: 28 start-page: 3636 year: 2010 ident: 814_CR10 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.28.3762 – year: 2019 ident: 814_CR32 publication-title: Neuro-Oncology doi: 10.1093/neuonc/noz207 – volume: 6 start-page: 12505 year: 2015 ident: 814_CR124 publication-title: Oncotarget doi: 10.18632/oncotarget.3723 – volume: 21 start-page: 189 year: 2019 ident: 814_CR118 publication-title: Neuro-Oncology doi: 10.1093/neuonc/noy146 – volume: 10 start-page: 49 issue: 2 year: 2018 ident: 814_CR85 publication-title: Cancers doi: 10.3390/cancers10020049 – volume: 15 start-page: 6002 year: 2009 ident: 814_CR8 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-0715 – volume: 74 start-page: 4836 year: 2014 ident: 814_CR82 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-0924 – volume: 512 start-page: 324 year: 2014 ident: 814_CR100 publication-title: Nature doi: 10.1038/nature13387 – volume: 17 start-page: 72 year: 2012 ident: 814_CR11 publication-title: Oncologist doi: 10.1634/theoncologist.2011-0386 – volume: 17 start-page: 225 year: 2010 ident: 814_CR13 publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.01.020 – volume: 12 start-page: 180 year: 2016 ident: 814_CR31 publication-title: Neuroimage Clin. doi: 10.1016/j.nicl.2016.06.018 – volume: 224 start-page: 334 year: 2011 ident: 814_CR12 publication-title: J. Pathol. doi: 10.1002/path.2913 – volume: 36 start-page: 2002 year: 2018 ident: 814_CR59 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.2002 – volume: 123 start-page: 3685 year: 2013 ident: 814_CR28 publication-title: J. Clin. Invest. doi: 10.1172/JCI69741 – volume: 4 start-page: 1737 year: 2013 ident: 814_CR69 publication-title: Oncotarget doi: 10.18632/oncotarget.1408 – volume: 31 start-page: 2020 year: 2017 ident: 814_CR62 publication-title: Leukemia doi: 10.1038/leu.2017.46 – volume: 77 start-page: 4102 year: 2017 ident: 814_CR80 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2263 |
| SSID | ssj0009087 |
| Score | 2.7117465 |
| SecondaryResourceType | review_article |
| Snippet | Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1580 |
| SubjectTerms | 631/208/737 631/80 Acute myeloid leukemia Animals Biomedical and Life Sciences Biomedicine Brain Neoplasms - genetics Cancer Research Cell Transformation, Neoplastic - genetics Cholangiocarcinoma Chondrosarcoma Decarboxylation Drug Resistance Epidemiology Glioma Glioma - genetics Humans Isocitrate dehydrogenase Isocitrate Dehydrogenase - genetics Leukemia Molecular Medicine Molecular modelling Mutants Mutation Oncology Review Review Article Therapeutic applications Thyroid cancer Thyroid carcinoma Tricarboxylic acid cycle Tumorigenesis |
| Title | IDH mutation in glioma: molecular mechanisms and potential therapeutic targets |
| URI | https://link.springer.com/article/10.1038/s41416-020-0814-x https://www.ncbi.nlm.nih.gov/pubmed/32291392 https://www.proquest.com/docview/2406924357 https://www.proquest.com/docview/2390159257 https://pubmed.ncbi.nlm.nih.gov/PMC7250901 |
| Volume | 122 |
| WOSCitedRecordID | wos000526251700003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: M7P dateStart: 20190101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 7X7 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1532-1827 dateEnd: 20241213 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 7RV dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: BENPR dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 8C1 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RFiEu5VkIlJWROIGsJrbT2FwQlFZFgtWqArS3KLEdiNQkS7Nb9efjcR7LUtELF1_sPJwZz0zm8Q3AqzDOZMKNpFmkMipUbqgUUUSzRB_GkckLWfhC4c_JdCrnczXrHW5tn1Y5yEQvqE2j0Ud-4Es0mVPuybvFL4pdozC62rfQ2IIdRElgPnVvtgbdDWWHmYnuOMXGqCaXB62InClC8efJKUVBrzb10jVj83rO5F-BU6-PTu79707uw25viZL3Hes8gFu2fgh3vvSx9kcw_fTxlFSrLlRPypr8OC-bKntLqqGjLqks1g2XbdWSrDZk0Swx98jd9I-qLtLlmreP4dvJ8dejU9p3X6A65odLyq1i1oSZM3BULoThhpmYxzYXOg6NEwaGSeMRz2Jd5FrJQiuncLGXj-KhyPkebNdNbZ8C0bkpCpZzy6UWAqtfWWHDTFqpldOhNoBw-Pap7qHJsUPGeepD5FymHblSR64UyZVeBfB6vGTR4XLctHh_oETaH9E2XZMhgJfjtDtcGDHJatus3BrvEVIM1zzp6D8-zUlChFRlASQbnDEuQODuzZm6_OkBvBNnd7obB_Bm4KH1a_1zE89u3sRzuMs8N2PS4j5sLy9W9gXc1pfLsr2YwFZy9h3HeeJH6UZ5FE1g58PxdHY28efmN0Q7Gg4 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoALb0qggJHgArKa2EljIyGEKNWuul31UKTeQmI7NFKTLM0ulD_Fb2TsPJalorceONtx4vjzzNjzzQzASz9KRcy1oGkgUxrKTFMRBgFNY7UdBTrLRe4ChSfxdCqOjuTBGvzqY2EsrbKXiU5Q61rZO_ItF6LJULnH72ffqK0aZb2rfQmNFhZ75ucPPLI178Y7uL6vGNv9dPhxRLuqAlRFfHtOuZHMaD9FxS2zMNRcMx3xyGShinyNINdMaJfJK1J5pqTIlURFYmvUSDz7ZxzHvQJX0YxgvqMKHiyT_PqizdFpr_8kG7yoXGw1YYCmD7WHNVTCIT1b1YPnjNvzHM2_HLVO_-3e_t_-3B241Vna5EO7Ne7CmqnuwfX9jktwH6bjnREpFy0VgRQV-XpS1GX6lpR9xWBSGhsXXTRlQ9JKk1k9t9wqHPSPqDXScumbB_D5UmbzENarujKPgKhM5znLuOFChaGN7mW58VNhhJJoIxgP_H6tE9WlXrcVQE4SRwHgImnhkSA8EguP5MyD18MjszbvyEWdN_uVTzoR1CTLZffgxdCMwsN6hNLK1Avs4268JLN9Nlq8DW9DSW9TxjIP4hUkDh1sYvLVlqo4dgnKY7SrcWAP3vSYXX7WPyfx-OJJPIcbo8P9STIZT_eewE3mdpIlaG7C-vx0YZ7CNfV9XjSnz9yeJPDlsqH8G8BgcW4 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgqpeeNOGFjASXEDWJrazsZEQQiyrrlpWewCpt5DYDo3UJEuzC-Wv9ddhO49lqeitB86eOHH8eWZsfzMD8MIPEx5RxXESiAQzkSrMWRDgJJLDMFBpxjMXKHwUTaf8-FjMNuCii4WxtMpOJzpFrSppz8gHLkSTGOMeDbKWFjEbjd_Nv2NbQcretHblNBqIHOpfP832rX47GZm5fknI-OPnDwe4rTCAZUiHC0y1IFr5iTHiImVMUUVUSEOdMhn6ygBeEa5cVq9QZqkUPJPCGBVbr0ZQn6XU9HsDbkZs6BNHG5ytEv76vMnXaY8CBelvVCkf1CwwbhC2GzdjkBk-X7eJlxzdy3zNvy5tnS0c3_mf_-JduN164Oh9s2TuwYYu78PWp5Zj8ACmk9EBKpYNRQHlJfp2mldF8gYVXSVhVGgbL53XRY2SUqF5tbCcK9PpH9FsqOHY1w_hy7WM5hFsllWpdwHJVGUZSammXDJmo35Jpv2Eay6F8R20B34377FsU7LbyiCnsaMGUB43UIkNVGILlfjcg1f9I_MmH8lVwvsdCuJWNdXxCgIePO-bjVKxN0VJqaulkXEnYYJYmZ0Ge_3bjAWwqWSJB9EaKnsBm7B8vaXMT1zi8sj426ZjD153-F191j8H8fjqQTyDLYPg-GgyPdyDbeIWleVt7sPm4mypn8At-WOR12dP3fJE8PW6kfwbIdp6NA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=IDH+mutation+in+glioma%3A+molecular+mechanisms+and+potential+therapeutic+targets&rft.jtitle=British+journal+of+cancer&rft.au=Han%2C+Sue&rft.au=Liu%2C+Yang&rft.au=Cai%2C+Sabrina+J&rft.au=Qian%2C+Mingyu&rft.date=2020-05-26&rft.eissn=1532-1827&rft.volume=122&rft.issue=11&rft.spage=1580&rft_id=info:doi/10.1038%2Fs41416-020-0814-x&rft_id=info%3Apmid%2F32291392&rft.externalDocID=32291392 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon |